JP2017509649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509649A5 JP2017509649A5 JP2016558023A JP2016558023A JP2017509649A5 JP 2017509649 A5 JP2017509649 A5 JP 2017509649A5 JP 2016558023 A JP2016558023 A JP 2016558023A JP 2016558023 A JP2016558023 A JP 2016558023A JP 2017509649 A5 JP2017509649 A5 JP 2017509649A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- seq
- dose
- body weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 230000037396 body weight Effects 0.000 claims 7
- 206010052779 Transplant rejections Diseases 0.000 claims 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims 5
- 230000002519 immonomodulatory effect Effects 0.000 claims 5
- 230000001506 immunosuppresive effect Effects 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 4
- 238000011269 treatment regimen Methods 0.000 claims 3
- 230000003442 weekly effect Effects 0.000 claims 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 238000011443 conventional therapy Methods 0.000 claims 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 2
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 description 12
- 241000282693 Cercopithecidae Species 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 241000282560 Macaca mulatta Species 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 229940109239 creatinine Drugs 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 230000010118 platelet activation Effects 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 102400000432 CD40 ligand, soluble form Human genes 0.000 description 2
- 101800000267 CD40 ligand, soluble form Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 229960005347 belatacept Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000007419 viral reactivation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461955588P | 2014-03-19 | 2014-03-19 | |
| US61/955,588 | 2014-03-19 | ||
| PCT/US2015/021551 WO2015143209A1 (en) | 2014-03-19 | 2015-03-19 | Methods of treating transplant rejection using a domain antibody directed against cd40l |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017509649A JP2017509649A (ja) | 2017-04-06 |
| JP2017509649A5 true JP2017509649A5 (enExample) | 2018-04-05 |
Family
ID=53055087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016558023A Withdrawn JP2017509649A (ja) | 2014-03-19 | 2015-03-19 | Ｃｄ４０ｌに対するドメイン抗体を用いる移植拒絶を治療する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20170051059A1 (enExample) |
| EP (1) | EP3119809A1 (enExample) |
| JP (1) | JP2017509649A (enExample) |
| KR (1) | KR20160124912A (enExample) |
| CN (1) | CN106132429A (enExample) |
| AU (1) | AU2015231180B2 (enExample) |
| BR (1) | BR112016018813A2 (enExample) |
| CA (1) | CA2943177A1 (enExample) |
| EA (1) | EA201691634A1 (enExample) |
| IL (1) | IL247048A0 (enExample) |
| MX (1) | MX2016011102A (enExample) |
| SG (1) | SG11201606521VA (enExample) |
| WO (1) | WO2015143209A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168759B2 (en) | 2008-07-18 | 2012-05-01 | Bristol-Myers Squibb Company | Compositions monovalent for CD28 binding and methods of use |
| SMT202000091T1 (it) | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| SG11201702383SA (en) * | 2014-09-30 | 2017-04-27 | Bristol Myers Squibb Co | Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28 |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| CA3006398A1 (en) * | 2015-11-27 | 2017-06-01 | Ablynx Nv | Polypeptides inhibiting cd40l |
| US20190086405A1 (en) | 2016-03-16 | 2019-03-21 | Bristol-Myers Squibb Company | Methods of diagnosing and treating lupus |
| EP3630843A2 (en) * | 2017-05-24 | 2020-04-08 | ALS Therapy Development Institute | Therapeutic anti-cd40 ligand antibodies |
| SMT202400527T1 (it) * | 2019-07-01 | 2025-01-14 | Tonix Pharma Ltd | Anticorpi anti-cd154 e loro usi |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| US8277810B2 (en) * | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| RS53073B (sr) * | 2003-11-04 | 2014-04-30 | Novartis Vaccines And Diagnostics Inc. | Upotreba antagonističkih anti-cd40 monoklonska antitela |
| LT1868635T (lt) | 2005-04-06 | 2017-07-10 | Bristol-Myers Squibb Company | Imuninių sutrikimų, susijusių su transplantato persodinimu, gydymo būdas tirpiomis mutantinėmis ctla4 molekulėmis |
| CA2634547C (en) | 2005-12-20 | 2016-10-11 | Bristol-Myers Squibb Company | Stable ctla4 formulation for subcutaneous administration |
| US8168759B2 (en) * | 2008-07-18 | 2012-05-01 | Bristol-Myers Squibb Company | Compositions monovalent for CD28 binding and methods of use |
| SMT202000091T1 (it) * | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
-
2015
- 2015-03-19 KR KR1020167028617A patent/KR20160124912A/ko not_active Ceased
- 2015-03-19 JP JP2016558023A patent/JP2017509649A/ja not_active Withdrawn
- 2015-03-19 US US15/122,455 patent/US20170051059A1/en not_active Abandoned
- 2015-03-19 EP EP15721055.0A patent/EP3119809A1/en not_active Withdrawn
- 2015-03-19 MX MX2016011102A patent/MX2016011102A/es unknown
- 2015-03-19 SG SG11201606521VA patent/SG11201606521VA/en unknown
- 2015-03-19 EA EA201691634A patent/EA201691634A1/ru unknown
- 2015-03-19 CA CA2943177A patent/CA2943177A1/en not_active Abandoned
- 2015-03-19 WO PCT/US2015/021551 patent/WO2015143209A1/en not_active Ceased
- 2015-03-19 BR BR112016018813A patent/BR112016018813A2/pt not_active Application Discontinuation
- 2015-03-19 AU AU2015231180A patent/AU2015231180B2/en not_active Ceased
- 2015-03-19 CN CN201580014085.1A patent/CN106132429A/zh active Pending
-
2016
- 2016-08-01 IL IL247048A patent/IL247048A0/en unknown
-
2020
- 2020-01-31 US US16/779,059 patent/US20200231676A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017509649A5 (enExample) | ||
| US20240174745A1 (en) | Antibody Constructs for CLDN18.2 and CD3 | |
| JP7682150B2 (ja) | プロテアーゼ活性化治療剤を含む組成物および方法 | |
| AU2018312251B2 (en) | Anti-CD39 antibodies, compositions comprising anti-CD39 antibodies and methods of using anti-CD39 antibodies | |
| US20180094072A1 (en) | Bi-Specific Monovalent Diabodies That are Capable of Binding CD123 and CD3, and Uses Thereof | |
| JP7665600B2 (ja) | 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法 | |
| KR20200031645A (ko) | 항cd8 항체 및 이의 용도 | |
| JP2018502060A5 (enExample) | ||
| JP2020515637A (ja) | 免疫腫瘍剤を伴うｐｓ標的化抗体を用いる癌の治療方法 | |
| JP6763529B2 (ja) | 抗クローディン−２モノクローナル抗体 | |
| SI2593128T1 (en) | Humanized antibodies targeting the EC1 Kaderina-11 domain and associated compositions and procedures | |
| KR20220019806A (ko) | 가용성 보체 수용체 1형 변이체 접합체 및 이의 용도 | |
| CA3037008A1 (en) | Methods for treating cancer with bavituximab based on levels of .beta.2-glycoprotein 1, and assays therefor | |
| AU2024239150A1 (en) | Cd19/cd38 multispecific antibodies | |
| KR20220159989A (ko) | C19 c38 이중특이적 항체 | |
| JP2017524675A5 (enExample) | ||
| CN103417965A (zh) | 一种含有抗vegf抗体的药物组合物 | |
| CA3238406A1 (en) | Bispecific antibody and use thereof | |
| CA3185332A1 (en) | Recombinant rhabdovirus encoding for a cd80 extracellular domain fc-fusion protein | |
| WO2025174812A1 (en) | Chimeric antigen receptor and/or synnotch receptor systems and cells and methods of their use | |
| CN120437287A (zh) | 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物 | |
| ES2860973T3 (es) | Diacuerpos monovalentes biespecíficos que pueden unirse a CD123 y CD3 y usos de estos | |
| WO2023036815A1 (en) | Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering | |
| HK40078027B (zh) | 针对ror1的抗体及其用途 |